340B Drug Pricing Program
The Centers for Medicare & Medicaid Services (CMS) Nov. 20 released an interim final rule implementing the Most Favored Nation (MFN) Model, a new payment model through the Center for Medicare and Medicaid Innovation (CMMI) that will cut Medicare Part B payments for certain drugs to the lowest鈥
America鈥檚 hospitals and health systems have very deep concerns about the substance and legality of today鈥檚 Most Favored Nation Model interim final rule. Instead of holding drug companies accountable for drug prices, it slashes reimbursement to hospitals for drugs.
The AHA on Friday sent a letter to the Health Resources and Services Administration鈥檚 Office of Pharmacy Affairs urging the agency to order drug manufacturers and their vendor Kalderos to immediately halt their conversion of the 340B program to a back-end rebate program.
The AHA on Friday sent a letter to the Health Resources and Services Administration鈥檚 Office of Pharmacy Affairs urging the agency to order drug manufacturers and their vendor Kalderos to immediately halt their conversion of the 340B program to a back-end rebate program.
The AHA today submitted
In a letter to Senator Lamar Alexander and Representative Greg Walden, AHA expresses strong support for the 340B Drug Pricing Program.
Please contact your representatives today and ask them to sign onto a bipartisan 鈥淒ear Colleague鈥 letter to Department of Health and Human Services Secretary Alex Azar expressing concern about recent efforts by Kalderos to transition the 340B Drug Pricing Program from one of up-front discounts to鈥
Please contact your representatives today and ask them to sign onto a bipartisan 鈥淒ear Colleague鈥 letter to Department of Health and Human Services Secretary Alex Azar expressing concern about recent efforts by Kalderos to transition the 340B Drug Pricing Program from one of up-front discounts to鈥
Please contact your representatives today and ask them to sign onto a bipartisan 鈥淒ear Colleague鈥 letter to Department of Health and Human Services Secretary Alex Azar expressing concern about recent efforts by Kalderos to transition the 340B Drug Pricing Program from one of up-front discounts to鈥
The full U.S. Court of Appeals for the District of Columbia Circuit denied AHA鈥檚 request to reconsider two decisions from this summer that upheld the Centers for Medicare & Medicaid Services鈥 cuts to payments for 340B drugs and for off-campus hospital outpatient clinic visits.